Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Archives of Osteoporosis
Erschienen in: Archives of Osteoporosis 1/2020

01.12.2020 | Review

Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts

verfasst von: Monique Chalem, Adriana Medina, Ana Karina Sarmiento, Deyanira Gonzalez, Carlos Olarte, Edgar Pinilla, Jorge Paz, Noemi Casas, Maria Paula Vega, Edna Diaz

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The justification for this consensus is the absence of local protocols on Medication-Related Osteonecrosis of the Jaws (MONJ), for prevention, evaluation, and treatment, involving physicians and dentists, leading to suspension of antiresorptive treatments, despite their benefit in the prevention of fragility fractures (40–70%). These fractures cause disability and mortality (80% and 20–30%, respectively), as opposed to the low risk associated with MONJ in osteoporotic (0.01–0.03%) and oncological patients (1.3–1.8%).

Purpose

To provide management recommendations through algorithms that guide health professionals to prevent, diagnose, and treat MONJ in different clinical scenarios.

Method

A technical multidisciplinary team composed of specialists with extensive experience in osteoporosis or osteonecrosis of the jaw from Fundación Santa Fé (Bogotá, Colombia) and the Asociación Colombiana de Osteoporosis y Metabolismo Mineral was selected. Three rounds were carried out: definition of questions, answers using Delphi methodology, and the discussion of questions in order to have an agreement. The whole group participated in two phases, and the developer group in the total number of rounds. A literature review was conducted to obtain academic support to design questions with clinical relevance.

Results and conclusions

The consensus group generated definitions and recommendations useful for doctors and dentists, following clinical algorithms involving four scenarios: osteoporosis patient who requires dental procedures and has not received antiresorptives, osteoporosis patient who are under treatment with antiresorptives, cancer patients, and MONJ-instituted patients. The therapeutic approach in osteoporosis and cancer patients, in invasive dental procedures, must be relied on the risk-benefit treatment.
Literatur
1.
Consensus Development Conference (1991) Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 90(1):107–110
2.
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA. 285(3):320–323PubMed
3.
Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 1103(2A):12S–17S discussion 17S-19S
4.
Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733
5.
Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347PubMed
6.
Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM et al (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272–2282PubMed
7.
Cummings SR, San Martin J, McClung M, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMed
8.
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523PubMed
9.
Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9(32):2643–2658PubMed
10.
Peterson MC, Stouch BJ, Martin SW et al (2005) The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J Bone Miner Res 20(Suppl 1):S293
11.
Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677–692PubMed
12.
Chan BH, Yee R, Puvanendran R, Ang SB (2018) Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. Singap Med J 259(2):70–75
13.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22(10):1479–1491PubMed
14.
Ruggiero SL, Dodson TB, Fantasia J et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 2014 update. J Oral Maxillofac Surg 72:1938–1956PubMed
15.
Junquera L, Gallego L (2008) Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 66(7):1516–1517PubMed
16.
Phal PM, Myall RW, Assael LA, Weissman JL (2007) Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 28(6):1139–1145PubMed
17.
Aghaloo T, Hazboun R, Tetradis S (2015) Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am 27(4):489–496PubMedPubMedCentral
18.
Chang J, Hakam AE, McCauley LK (2018) Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr Osteoporos Rep 16(5):584–595PubMed
19.
Sambrook PN, Ebeling P (2008) Osteonecrosis of the jaw. Curr Rheumatol Rep 10:97–101PubMed
20.
Nicoletti P, Cartsos VM, Palaska PK et al (2012) Genome wide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 17:279PubMedPubMedCentral
21.
Zhong D-N, Wu J-Z, Li G-J (2013) Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis. Acta Haematol 129:90–95PubMed
22.
Silverman SL, Landesberg R (2009) Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 122:S33–S45PubMed
23.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) Task force on bisphosphonate-related osteonecrosis of the jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 35(3):119–130PubMed
24.
Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A (2014) Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol 10(2):257–275PubMed
25.
Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY et al (2016) Osteonecrosis of the jaw in the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS). J Bone Miner Res 31(2):336–340PubMed
26.
Palaska PK, Cartsos V, Zavras AI (2009) Bisphosphonates and time to osteonecrosis development. Oncologist. 14(11):1154–1166PubMed
27.
Gebara SN, Moubayed H (2009) Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. Am J Health Syst Pharm 66(17):1541–1547PubMed
28.
29.
Otto S, Tröltzsch M, Jambrovic V, Panya S, Probst F, Ristow O et al (2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 43(6):847–854PubMed
30.
Bagan J, Peydró A, Calvo J, Leopoldo M, Jiménez Y, Bagan L (2016) Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. Oral Dis 22(4):324–329PubMed
31.
Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, Tan W, Body JJ, Migliorati C, Lalla RV (2018) MASCC Bone Study Group. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27(2):383–394PubMed
32.
Karna H, Gonzalez J, Radia HS, Sedghizadeh PP, Enciso R (2018) Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: a systematic review with meta-analyses. Oral Oncol 85:15–23PubMed
33.
Nazir MA (2017) Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim) 11(2):72–80
34.
Niibe K et al (2015) Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J Prosthodontic Res 59(1):3–5
35.
Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG et al (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27(32):5356–5362PubMed
36.
Stockmann P, Nkenke E, Englbrecht M, Schlittenbauer T, Wehrhan F, Rauh C et al (2013) Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 41(1):71–75PubMed
37.
López-Delgado L, Riancho-Zarrabeitia L, Riancho JA (2016) Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis. Expert Opin Drug Metab Toxicol 12(4):389–398PubMed
38.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527–534PubMed
39.
Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580–8587PubMed
40.
Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY (2015) Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 22:151–165PubMedPubMedCentral
41.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822PubMed
42.
Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M et al (2011) The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 141(11):1365–1370
43.
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3–23PubMed
44.
Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96(6):1727–1736PubMed
45.
Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26(12):2773–2783PubMedPubMedCentral
46.
Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G (2016) Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent 6(2):97–104PubMedPubMedCentral
47.
Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF (2011) Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 1218:47–54PubMed
48.
Barasch J, Cunha-Cruz FA, Curro P, Hujoel AH, Sung D, Vena AE, Voinea-Griffin, the CONDOR Collaborative Group† (2011) Risk factors for osteonecrosis of the jaws a case-control study from the CONDOR dental PBRN. J Dent Res 90(4):439–444PubMedPubMedCentral
49.
Bone HG, Chapurlat R, Brandi M-L et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483–4492PubMedPubMedCentral
50.
Christodoulou C, Pervena A, Klouvas G et al (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209–211PubMed
51.
Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H et al (2014) Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 15(1):114–122PubMed
52.
Scagliotti GV, Hirsh V, Siena S et al (2012) Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 7:1823PubMed
53.
Dimopoulos MA, Kastritis E, Anagnostopoulos A et al (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91(7):968–971PubMed
54.
Dodson TB (2015) The frequency of medication-related osteonecrosis of the jaw and its associated risk factors. Oral Maxillofac Surg Clin North Am 27(4):509–516PubMed
55.
Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, Sendo T (2015) Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull 38(12):1850–1855PubMed
56.
Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT (2010) Bisphosphonate Osteonecrosis Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support. Care Cancer 18:1099–1106
57.
Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ (2018) Osteonecrosis of the jaws: a review and update in etiology and treatment. Braz J Otorhinolaryngol 84(1):102–108
58.
Rabelo GD, Assunção JN, Chavassieux P, Soares HA, Alves FA, Lemos CA (2014) Bisphosphonate-related osteonecrosis of the jaws and its array of manifestations. J Maxillofac Oral Surg 14(3):699–705PubMedPubMedCentral
59.
Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Grötz KA (2016) Dental implants in patients treated with antiresorptive medication - a systematic literature review. Int J Implant Dent 2(1):9PubMedPubMedCentral
60.
Holzinger D, Seemann R, Matoni N, Ewers R, Millesi W, Wutzl A (2014) Effect of dental implants on bisphosphonates related osteonecrosis of the jaws. J Oral Maxillofac Surg 72(10):1937.e1
61.
Jacobsen C, Metzler P, Rössle M, Obwegeser J, Zemann W, Grätz K (2013) Osteopathology induced by bisphosphonates and dental implants: clinical observation. Clin Oral Investig 17(1):167–175PubMed
62.
Ata-Ali J, Ata-Ali F, Peñarrocha-Oltra D, Galindo-Moreno P (2014) What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res 27(2):38–46
63.
Alsabbagh M, Robinson F, Romanos G, Thomas M (2015) Osteoporosis and bisphosphonate-related osteonecrosis in a dental school implant patient population. Implant Dent 24(3):328–332
64.
Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P (2017) The prevention of medication-related osteonecrosis of the jaw. Dtsch Arztebl Int 114(5):63–69PubMedPubMedCentral
65.
Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi et al (2017) A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int 28(8):2465–2473PubMed
66.
Ripamonti CI, Maniezzo M, Campa T et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145PubMed
67.
Ferlito S, Liardo C, Puzzo S (2010) Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series. Minerva Stomatol 59:593–601PubMed
68.
McClung M, Harris ST, Miller PD et al (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13–20PubMed
69.
Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369–376
70.
71.
Zandi M, Dehghan A, Mohammadi-Mofrad A, Amini P, Vahdatinia F (2017) Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats. J Craniomaxillofac Surg 45(2):275–228PubMed
72.
Livio F (2018) Pharmacovigilance update. Rev Med Suisse 14(588-589):81–84PubMed
73.
Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410PubMed
74.
Atalay B, Yalcin S, Emes Y et al (2011) Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? Lasers Med Sci 26:815–823PubMed
75.
Kunchur R, Need A, Hughes T, Goss A (2009) Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:1167–1173PubMed
76.
Lee CY, Suzuki JB (2010) CTX biochemical marker of bone a reliable predictor of bisphosphonate-associated osteonecrosis of metabolism. Is it the jaws after surgery? Part II: a prospective clinical study. Implant Dent 19:29–38PubMed
77.
O’Connell JE, Ikeagwani O, Kearns GJ (2012) A role for C-terminal crosslinking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery? Ir J Med Sci 181:237–242PubMed
78.
McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 114(5):999–1007PubMed
79.
Morris PG, Fazio M, Farooki A et al (2012) Serum N-telopeptide and bone specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases. J Oral Maxillofac Surg 70:2768–2775PubMed
80.
Lehrer S, Montazem A, Ramanathan L et al (2009) Bisphosphonate induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 67:159–161PubMed
81.
Medina A, Rosero O, Rueda PN, Sánchez F, Chalem M, González MA et al. (2018) II Consenso Colombiano para el manejo de la osteoporosis posmenopáusica. Rev Colomb Reumatol
82.
Johansson H, Oden A, Kanis JA et al (2014) A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int 94:560–567PubMed
83.
Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H et al (2015) Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg 44(12):1558–1564PubMed
84.
Kagami H, Inoue M, Kobayashi A, Taguchi A, Li X, Yoshizawa M (2018) Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws. Oral Dis 24(1-2):52–56PubMed
85.
Yamachika E, Matsubara M, Ikeda A, Matsumura T, Moritani N, Iida ST (2015) Treatment of osteonecrosis of the jaw. J Craniofac Surg 26(7):e575–e577PubMed
86.
Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D et al (2017) Case-Based review of osteonecrosis of the jaw (ONJ) and application of the International Recommendations for Management from the International Task Force on ONJ. J Clin Densitom 20(1):8–24PubMed
87.
Guarneri V, Miles D, Robert N et al (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181PubMed
88.
Yamashita J, McCauley LK (2012) Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract 12:233PubMed
89.
Bonacina R, Mariani U, Villa F et al (2011) Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 77:b147PubMed
90.
Lo JC, O’Ryan FS (2010) Gordon NP, et al: (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243PubMed
91.
92.
Greenspan S, Perera S, Ferchak MA, Nace D, Resnick N (2015) Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical Trial. JAMA Intern Med 175(6):913–921PubMedPubMedCentral
93.
Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR (2012) Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. Bone. 50(6):1389–1393PubMed
94.
Henry DH, Costa L (2011) Goldwasser F, et al: (2006) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125PubMed
95.
Kademani D, Koka S, Lacy MQ et al (2006) Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81:1100PubMed
96.
Fedele S, Porter SR, D’Aiuto F et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060PubMed
97.
Boff C, Salum FG, Figueredo MA, Cherubini K (2014) Important aspects regarding the role of microorganisms in bisphosphonates-related osteonecrosis of the jaw. Arch Oral Biol 59:790–799PubMed
98.
O’Halloran M, Boyd NM, Smith A (2014) Denosumab and osteonecrosis of the jaws–the pharmacology, pathogenesis and a report of two cases. Aust Dent J 59:516–519PubMed
99.
Thumbigere-Math V, Michalowicz BS, Hughes PJ et al (2015) Serum markers of bone turnover and angiogenesis in patients with bisphosphonate-related osteonecrosis of the jaw after discontinuation of long-term intravenous bisphosphonate therapy. J Oral Maxillofac Surg 74(4):738–746PubMedPubMedCentral
100.
Badr M, Kyriakidou E, Atkins A, Harrison S (2017) Aggressive denosumab-related jaw necrosis - a case series. Br Dent J 223(1):13–16PubMed
Metadaten
Titel
Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts
verfasst von
Monique Chalem
Adriana Medina
Ana Karina Sarmiento
Deyanira Gonzalez
Carlos Olarte
Edgar Pinilla
Jorge Paz
Noemi Casas
Maria Paula Vega
Edna Diaz
Publikationsdatum
01.12.2020
Verlag
Springer London
Erschienen in
Archives of Osteoporosis / Ausgabe 1/2020
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-020-00761-0

Weitere Artikel der Ausgabe 1/2020

Archives of Osteoporosis 1/2020 Zur Ausgabe

Original Article

Association between osteoporotic femoral neck fractures and DXA-derived 3D measurements at lumbar spine: a case-control study

Original Article

“Effect of very dense artifacts on Hologic and general electric bone densitometry results”

Original Article

Association of bone mineral density with the development of knee osteoarthritis in men and women: a cross-sectional study using the fourth and fifth Korea National Health and Nutrition Examination Surveys

Original Article

The use of clozapine is protective for low bone mineral density induced by prolactin-raising antipsychotics in inpatients with schizophrenia

Original Article

Comparison of screening tools for optimizing fracture prevention in Canada

Original Article

Prevalence and factors of T-score discordance between hip and spine among middle-aged and elderly Malaysians

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

16.04.2024 | Spondylitis ankylosans | Nachrichten

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!
weitere anzeigen

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise